Pay in 4 interest-free payments of $29.75 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Avermectin B1a-Avermectin B1b mixt
GP130 receptor agonist-1 (Compound 2) treatment showed a 2-fold increase in phosphorylation of STAT3 within 10 min at its regulatory Tyr705 site
Solubility: DMSO : ≥ 100 mg/mL (304
and monoamine oxidases (MAO-A and MAO-B) and catechol-O-methyl transferase (COMT) inhibition
InChi: InChI=1S/C48H73N11O17/c1-6-24(4)39(47(74)59-19-7-8-34(59)46(73)53-28(13-16-35(50)61)41(68)54-30(48(75)76)14-17-36(51)62)58-45(72)31(20-23(2)3)56-43(70)32(21-26-9-11-27(60)12-10-26)57-42(69)29(15-18-37(63)64)52-44(71)33(22-38(65)66)55-40(67)25(5)49/h9-12
Deoxyshikonin Size:Contact [email protected] for quotation Avermectin B1a-Avermectin B1b mixtDeoxyshikonin is isolated from Lithospermum erythrorhizon Sieb with antitumor activity. Deoxyshikonin increases the expression of VEGF C and VEGF A mRNA in HMVEC dLy, promotes HIF 1 and HIF 1 subunit interaction and binds to specific DNA sequences targeted by HIF, indicates a prolymphangiogenesis as well as a proangiogenesis effect in vitro. Deoxyshikonin shows significant synergic antimicrobial activity against S. pneumonia (MIC=17 g mL), also shows
US$ 115.00
US$ 155.00
US$ 44.95
US$ 1347.50
US$ 986.50
US$ 110.00
US$ 575.98
US$ 420.00
US$ 200.47
US$ 135.00
US$ 50.00
US$ 12.25
US$ 125.00
US$ 93.95